<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>Inbox Robot: Gilead Sciences News</title>
<link>http://www.inboxrobot.com/news/gilead-sciences</link><description>Constantly updated news and information about a variety of topics.</description><item>
<title>PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS</title>
<link>http://www.inboxrobot.com/news.php?fid=177736265</link>
<pubDate>9 Jul 2008 09:56 GMT</pubDate>
<description>
...  Biblio Info - Jul. 08, 2008 Pub. Number WO2008077650 Appl. Data EP07011495 20071224 Applicant GILEAD SCIENCES, INC. Inventor(s) BONDY, Steven, S. WATKINS, William, John CHONG, Lee, Shun HERDEWIJN, Piet, Andr,  ...
</description>
</item><item>
<title>Pharmasset Announces Initiation Of Combination Study Of Clevudine And Viread(R) For HBV By French National Agency For Research On AIDS And Hepatitis</title>
<link>http://www.inboxrobot.com/news.php?fid=177731338</link>
<pubDate>9 Jul 2008 09:30 GMT</pubDate>
<description>
...  AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc. (Nasdaq: VRUS) and Gilead Sciences, Inc. (Nasdaq: GILD), has initiated the first head-to-head study of clevudine and (R) (tenofovir  ...
</description>
</item><item>
<title>Pharmasset Announces Initiation of Combination Study of...</title>
<link>http://www.inboxrobot.com/news.php?fid=177690690</link>
<pubDate>9 Jul 2008 04:26 GMT</pubDate>
<description>
...  filings with the Securities and Exchange Commission. Viread and Hepsera are registered trademarks of Gilead Sciences, Inc. ...
</description>
</item><item>
<title>Gilead Sciences to Release Second Quarter 2008 Financial...</title>
<link>http://www.inboxrobot.com/news.php?fid=177690689</link>
<pubDate>9 Jul 2008 04:26 GMT</pubDate>
<description>
...  has operations in North America, Europe and Australia. &lt;p class=&quot;bwtextalignleft&quot; For more information on Gilead Sciences, please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). ...
</description>
</item><item>
<title>Finding Wealth In Health</title>
<link>http://www.inboxrobot.com/news.php?fid=177651515</link>
<pubDate>8 Jul 2008 21:31 GMT</pubDate>
<description>
...  prime time to stock up on early growth stocks. Brownes stable health-care play is Gilead Sciences For a more risky move, Browne recommends buying stock in the health club industry,  ...
</description>
</item><item>
<title>Biotechnology stocks close higher as Wall Street forecasts positive 2nd - quarter earnings</title>
<link>http://www.inboxrobot.com/news.php?fid=177648797</link>
<pubDate>8 Jul 2008 21:13 GMT</pubDate>
<description>
...  biotechnology companies in the coming weeks. Here&apos;s how several key biotechnology stocks performed Tuesday: Gilead Sciences Inc., up $1.86, or 3.6 percent, to $53.53. ...
</description>
</item><item>
<title>Gilead Sciences to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008</title>
<link>http://www.inboxrobot.com/news.php?fid=177641424</link>
<pubDate>8 Jul 2008 20:25 GMT</pubDate>
<description>
...  1-617-801-6888 (international) and dial the participant passcode 84267247. The webcast will be archived on Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of  ...
</description>
</item><item>
<title>Biotechnology stocks open higher on rising market as Fed tries to alleviate bank concerns</title>
<link>http://www.inboxrobot.com/news.php?fid=177590007</link>
<pubDate>8 Jul 2008 14:32 GMT</pubDate>
<description>
...  its lending efforts to investment banks. Here&apos;s how several key biotechnology stocks performed Tuesday: Gilead Sciences Inc., up 66 cents at $52.34. ...
</description>
</item><item>
<title>Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team</title>
<link>http://www.inboxrobot.com/news.php?fid=177587674</link>
<pubDate>8 Jul 2008 14:30 GMT</pubDate>
<description>
...  plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University&apos;s emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial  ...
</description>
</item><item>
<title>Pharmasset Announces Initiation of Combination Study of Clevudine and Viread for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</title>
<link>http://www.inboxrobot.com/news.php?fid=177582190</link>
<pubDate>8 Jul 2008 13:50 GMT</pubDate>
<description>
...  filings with the Securities and Exchange Commission. Viread and Hepsera are registered trademarks of Gilead Sciences, Inc. CONTACT: Kurt Leutzinger, Chief Financial Officer, Pharmasset, Inc.,+1-609-613-4110, Terms and conditions of use  ...
</description>
</item><item>
<title>Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Re</title>
<link>http://www.inboxrobot.com/news.php?fid=177568101</link>
<pubDate>8 Jul 2008 12:38 GMT</pubDate>
<description>
...  AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc. (Nasdaq: VRUS) and Gilead Sciences, Inc. (Nasdaq: GILD), has initiated the first head-to-head study of clevudine and Viread(R) (tenofovir  ...
</description>
</item><item>
<title>Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</title>
<link>http://www.inboxrobot.com/news.php?fid=177561658</link>
<pubDate>8 Jul 2008 12:21 GMT</pubDate>
<description>
...  filings with the Securities and Exchange Commission. Viread and Hepsera are registered trademarks of Gilead Sciences, Inc. Disclaimer: Information contained on this page is provided by companies featured through PR  ...
</description>
</item><item>
<title>Biotechnology stocks close mixed as the broader market falls over economic worries</title>
<link>http://www.inboxrobot.com/news.php?fid=177543058</link>
<pubDate>8 Jul 2008 10:53 GMT</pubDate>
<description>
...  more troubles in the financial sector. Here&apos;s how several key biotechnology stocks performed Monday: Gilead Sciences Inc., up 58 cents to $51.67. ...
</description>
</item><item>
<title>Inside Scoop: Copart Insiders Trade Places</title>
<link>http://www.inboxrobot.com/news.php?fid=177471675</link>
<pubDate>7 Jul 2008 21:30 GMT</pubDate>
<description>
...  | Companies Featured in This Article: Copart, Metalico, Equinix, Seachange International, Liberty Global, HealthExtras, Gilead Sciences, Omnicare, American Superconductor, SuccessFactors SHARES OF COPART HAVE been riding high for the past  ...
</description>
</item><item>
<title>Copart Insiders Trade Places</title>
<link>http://www.inboxrobot.com/news.php?fid=177471626</link>
<pubDate>7 Jul 2008 21:30 GMT</pubDate>
<description>
...  | Companies Featured in This Article: Copart, Metalico, Equinix, Seachange International, Liberty Global, HealthExtras, Gilead Sciences, Omnicare, American Superconductor, SuccessFactors SHARES OF COPART HAVE been riding high for the past  ...
</description>
</item></channel>
</rss>
